First-line pembrolizumab versus dabrafenib/trametinib treatment for BRAF V600-mutant advanced melanoma

Mendeley Data2024-01-31 更新2024-06-26 收录

黑色素瘤治疗

靶向治疗

数据链接：

https://data.mendeley.com/datasets/bdjx5bcgtw 数据链接链接失效反馈

官方服务：

资源简介：

This is a supplementary material for the article JAAD-D-22-01092R1, First-line pembrolizumab versus dabrafenib/trametinib treatment for BRAF V600-mutant advanced melanoma.

创建时间：

2024-01-31

Additional file 2 of Total serum N-glycans associate with response to immune checkpoint inhibition therapy and survival in patients with advanced melanoma

黑色素瘤治疗

血清尿酸

Additional file 2: Table 1. Description of total serum N-glycan UHPLC measured peaks. Table 2. Description of total serum derived traits. Table 3. Summary statistics for the associations between N-gly

DataCite Commons2023-04-13 更新60

Prospective Multicentric Randomized Study of Glivec in Advanced GIST Expressing C-kit: Interruption After 5 Years vs Maintenance

胃肠道间质瘤治疗

靶向治疗

Gastrointestinal stromal tumors (GISTs) are associated with a dismal prognosis in localized and advanced phase with a major resistance to conventional chemotherapy agents. Virtually all malignant GIST

NIAID Data Ecosystem40

Data_Sheet_1_Enhanced Anticancer Effect of a Combination of S-adenosylmethionine (SAM) and Immune Checkpoint Inhibitor (ICPi) in a Syngeneic Mouse Model of Advanced Melanoma.PDF

黑色素瘤治疗

免疫疗法

Immune checkpoint inhibitors (ICPi) targeting the PD-1/PD-L1 pathway have shown marked success in patients with advanced melanoma. However, 60–70% of patients fail to respond, warranting a therapeutic

NIAID Data Ecosystem40

Supplementary Material for: Sequential Myelomatous Pleural and Pericardial Effusions in Multiple Myeloma: A Case Report Demonstrating Extended Survival with Teclistamab

多发性骨髓瘤

靶向治疗

Abstract Background: Myelomatous pleural effusion (MPE) and pericardial involvement are rare manifestations of multiple myeloma, occurring in less than 1% of cases and carrying historically poor progn

DataCite Commons2025-04-17 更新60

Table_2_Comparative Risks of High-Grade Adverse Events Among FDA-Approved Systemic Therapies in Advanced Melanoma: Systematic Review and Network Meta-Analysis.docx

黑色素瘤治疗

不良事件分析

Background: Head-to-head evidence is lacking in comparative risks of high-grade adverse events (AEs) among different systemic treatment options for advanced melanoma. Methods: An up-to-date systematic

NIAID Data Ecosystem40

First-line pembrolizumab versus dabrafenib/trametinib treatment for BRAF V600-mutant advanced melanoma

资源简介：

相关数据集